EICHORCondition: Prostate Cancer · Prostate Neoplasm · Sponsor: Radboud University Medical Center
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
In the Netherlands, most men with prostate cancer (PCa) are treated with radical whole-gland treatment, i.e. prostatectomy or radiotherapy. The burden of complications such as incontinence and erectile dysfunction associated with radical treatment is considerable. A recent systematic review by our group has shown that focal therapy of PCa seems to reduce the burden of treatment side-effects in men with intermediate-risk disease, maintaining their quality of life without compromising oncological effectiveness. The costs of side effects that can be prevented are estimated at €5456 per patient, resulting in total expected cost savings of about €22 million per year in The Netherlands. Furthermore, exploration of the benefit-risk balance under patients showed that they are willing to sacrifice some survival for an improvement in quality of life (QoL). Focal therapy comprises a modern alternative to selectively treat a specific part of the prostate while preserving the rest of the gland. There is, however, a lack of high-quality evidence, and numerous papers therefore recommend to perform a multicenter randomized controlled trial (RCT). The RCT should have long-term follow-up, predefined assessment of cancer-specific and health-related QoL outcome measures, and economic evaluations to inform policymakers regarding cost-effectiveness. This RCT on focal therapy versus usual care is urgently needed to enable focal therapy to overgrow the experimental status, provide the evidence need…
This description comes directly from the study's public registry record.
Lauren te Molder · +31243611111 · Lauren.teMolder@radboudumc.nl
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Gleason score of 7 (3 + 4 or 4 + 3; ISUP grade 2/3) * PSA level of ≤ 20 ng/ml * Clinical stage ≤ T2b disease * Life expectancy of ≥ 10 years * Men with a prostate size ≤ 5 cm in sagittal length and ≤ 6 cm in axial length * Fit, eligible, and normally destined for radical surgery or radiotherapy * No concomitant cancer * No previous treatment of their prostate * An understanding of the Dutch language sufficient to receive written and verbal information about the trial, its consent process and the study questionnaires Exclusion Criteria: * Unfit for general anesthesia or radical surgery * Low volume low-risk disease (≤4mm Gleason score of ≤ 6 / ISUP grade 1) * High-risk disease (Gleason score of ≥ 8 / ISUP grade \>3) * Clinical T3 disease (extracapsular PCa) * Men who have received previous active therapy for PCa. * Men with evidence of extraprostatic disease. * Men with an inability to tolerate a transrectal ultrasound. * Cardiac pacemaker * Metal implants/stents in the urethra or prostate. * ASA ≥4 * Prostatic calcification/cysts that interfere with effective delivery of TULSA/HIFU based on MRCT. * Men with renal impairment and a glomerular filtration rate (GFR) of \< 30 ml/minute/1.73 m2. * Unable to give consent to participate in the trial, as judged by the attending clinicians
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Radboud University Medical Centre | Nijmegen, Gelderland, Netherlands | Recruiting |
| Hifu kliniek | Etten-Leur, North Brabant, Netherlands | Not Yet Recruiting |
| Amsterdam UMC | Amsterdam, North Holland, Netherlands | Not Yet Recruiting |
| Isala klinieken | Zwolle, Overijssel, Netherlands | Not Yet Recruiting |
| St. Antonius hospital | Nieuwegein, Utrecht, Netherlands | Not Yet Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06223295